US NIAID cancels novel HIV vaccine trial
This article was originally published in Scrip
The protracted search for an effective vaccine to prevent HIV has been dealt another blow after the US National Institute of Allergy and Infectious Diseases (NIAID), part of theNIH, decided not to conduct a large Phase IIb study with its potentially promising candidate, although a smaller study is being considered.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.